Cardiovascular medications frequently lead the polypharmacy category, often contributing to adverse clinical outcomes, and the most vulnerable among us are often prescribed the most complex regimens.

We want to hear from you. Tell us what you think here or leave a comment on the app's iTunes or Google Play page. The updated ASCVD Risk Estimator Plus uses up-to-date ACC clinical policy and user ...

A unique blend of forum and network, the Cardiovascular (CV) Team Member Section and Leadership Council is advancing ACC's efforts to identify and address gaps in areas of professional importance to ...

With your help, ACC Advocacy actively works with Congress, state legislators, and other key decision makers to transform cardiovascular care and improve heart health. However, we need everyone's voice ...